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Abstract 
We describe an 8-mm hepatocellular carcinoma (HCC) with hepatitis C virus-related 
cirrhosis in a 74-year-old woman. Ultrasound (US) revealed an 8-mm hyperechoic nodule 
in segment 6 of the liver. Contrast-enhanced computed tomography (CT) and US 
revealed no hypervascularity in the early phase and no washout in the late phase and the 
Kupffer phase, respectively. CT during arteriography revealed no hypervascularity and CT 
during arterial portography disclosed no perfusion defect. Gadolinium-ethoxybenzyl-
diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance 
imaging (MRI) revealed no hypervascularity in the early phase, but disclosed a defect in 
the hepatobiliary phase. Histologically, the nodule was diagnosed as well-differentiated 
HCC characterized by more than two-fold the cellularity of the non-tumorous area, with a 
high nuclear:cytoplasmic ratio, increased cytoplasmic eosinophilia, fatty change, and 
slight cell atypia with an irregular thin trabecular pattern. Our case demonstrates the 
utility of Gd-EOB-DTPA-enhanced MRI in the diagnosis of small HCC. 
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Introduction 
Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) is a 
new liver-specific contrast agent used in magnetic resonance imaging (MRI). A bolus 
injection of Gd-EOB-DTPA allows the evaluation of tumor vascularity in a manner 
similar to evaluation with gadolinium-triamine pentaacetic acid (Gd-DTPA) [1]. 
Moreover, it begins to accumulate in normally functioning hepatocytes in the 
hepatobiliary phase [1, 2] 20 min after injection, thereby enhancing the liver parenchyma. 
On the other hand, tumors appear like hypointense lesions because they lack normally 
functioning hepatocytes [2, 3]. 
Here, we describe an 8-mm well-differentiated hepatocellular carcinoma (HCC) 
detected in the hepatobiliary phase (20 min after injection), whereas contrast-enhanced 
ultrasound (US) and computed tomography (CT) did not reveal hypervascularity in the 
early phase and washout in the late phase; also, CT during arteriography (CTA) and CT 
during arterial portography (CTAP) did not reveal hypervascularity and perfusion defect, 
respectively. 
Case Report 
A 74-year-old woman with hepatitis C virus (HCV)-related cirrhosis was admitted to Kobe Asahi 
Hospital in April 2008 for further examination of an 8-mm hyperechoic nodule in segment 6. HCV 
antibody and HCV RNA were positive, hepatitis B surface antigen and hepatitis B virus DNA were 
negative, and laboratory data on admission disclosed the following values: platelets 7.2 × 10
4/μl (normal 
13.0–36.9), aspartate aminotransferase 26 IU/l (10–40), alanine aminotransferase 20 IU/l (5–40), thymol 
turbidity 18.5 U/l (0–4), zinc surface turbidity 13.7 U/l (2–12), indocyanine green retention rate at 
15 min 7% (0–10), and γ-globulin 23.3% (10.6–20.5). The levels of tumor markers revealed the 
following: α-fetoprotein 7.1 ng/ml (0–9.9), protein induced by vitamin K absence II 42 mAU/ml (0–40). 
US disclosed an 8-mm hyperechoic nodule in segment 6 (fig. 1). Contrast-enhanced CT revealed no 
hypervascularity in the early phase and no washout in the late phase. Contrast-enhanced US revealed no 
hypervascularity in the early vascular phase and no defect in the Kupffer phase. CTA revealed no 
hypervascularity and CTAP revealed no perfusion defect. Superparamagnetic iron oxide (SPIO)-MRI 
revealed isointensity in both T1 and T2 sequences. Gd-EOB-DTPA-enhanced MRI revealed no 
hypervascularity in the early phase, but disclosed a defect in the hepatobiliary phase (fig. 2). 
Histologically, the nodule was diagnosed as well-differentiated HCC characterized by more than 
two-fold the cellularity of the non-tumorous area, with a high nuclear:cytoplasmic ratio, increased 
cytoplasmic eosinophilia, fatty change, and slight cell atypia with an irregular thin trabecular pattern 
(fig. 3). The HCC was treated with radiofrequency ablation, and the ablated HCC was confirmed by 
Gd-EOB-DTPA-enhanced MRI. Complete necrosis of the tumor was revealed by US-guided biopsy. 
Discussion 
HCC is known to arise multicentrically in cases of virally induced liver cirrhosis, 
developing from dysplastic nodules into HCC [4, 5]. When considering the most 
appropriate therapeutic approach, it is important to distinguish between dysplastic 
nodules and HCC. Although the usefulness of detecting hypervascular HCCs has been 
reported [1], neither hypovascular lesions nor lesions with weakly increased arterial flow 
have been evaluated to date. These latter nodules are difficult to evaluate in dynamic 
studies with Gd-DTPA. No significant quantitative difference is observed between HCCs 
and dysplastic nodules in terms of the enhancement ratios and the contrast-to-noise ratio 
[6]. A combination of CTA and CTAP, as well as SPIO-enhanced MRI, has been 
conducted to distinguish between these two entities [7, 8]. It is known that SPIO 
accumulates in some HCCs [8]. SPIO-enhanced MRI, however, is of limited use in the  
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evaluation of HCCs, being by itself insufficient for determining the therapeutic strategy 
for the treatment of HCCs. When a combination of CTA and CTAP is used [7], the blood 
supply is very informative in evaluating the malignancy of liver lesions. CTA and CTAP 
are too invasive, however, for routine application. 
In our case, imaging studies by modalities such as contrast-enhanced US and CT 
revealed no hypervascularity in the early phase and no washout in the Kupffer phase and 
the late phase. CTA did not reveal hypervascularity, and CTAP did not reveal perfusion 
defect. We have emphasized the superiority of CT arterioportal angiography to 
contrast-enhanced CT and MRI in the diagnosis of HCC in nodules smaller than 20 mm 
[9]. We have also detected a 10-mm well-differentiated HCC showing perfusion defect at 
CTAP, when contrast-enhanced US, CT, and MRI revealed no hypervascularity in the 
early phase or washout in the late phase, and CTA showed no hypervascular stain [9]. In 
this study, however, even with CT arterioportal angiography, we were not able to detect 
the 8-mm HCC. Although the data remain preclinical, specific enhancement with 
Gd-EOB-DTPA has been reported for the differentiation of HCC [10]. Gd-EOB-DTPA-
enhanced MRI provides additional diagnostic clues – the level of hepatocyte function and 
excretion [11]. We detected an 8-mm HCC with Gd-EOB-DTPA-enhanced MRI, 
showing a defect in the hepatobiliary phase (20 min after injection). Our case 
demonstrates the utility of Gd-EOB-DTPA-enhanced MRI in the diagnosis of small HCC, 
even of an 8-mm nodule, although all nodules recognized as hypointense in the 
hepatobiliary phase and diagnosed as HCCs are associated with potential misdiagnosis. In 
our case the well-differentiated HCC was confirmed histologically. 
Further study is needed to compare the utility of Gd-EOB-DTPA-enhanced MRI with 
contrast-enhanced US, CT, and CT arterioportal angiography in the diagnosis of HCC in 
nodules smaller than 20 mm. 
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Fig. 1. US disclosed an 8-mm hyperechoic nodule in segment 6. 
 
 
 
Fig. 2. Gd-EOB-DTPA-enhanced MRI disclosed a defect in the hepatobiliary phase. 
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Fig. 3. Histologically, the nodule was diagnosed as well-differentiated HCC characterized by more than 
two-fold the cellularity of the non-tumorous area, with a high N/C ratio, increased cytoplasmic 
eosinophilia, fatty change, and slight cell atypia with an irregular thin trabecular pattern. 
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